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Abstract
Human breast cancer resistance protein (BCRP)/MXR/ABCG2 is a well-recognized ABC half-
transporter that is highly expressed at the apical membrane of many normal tissues and cancer 
cells. BCRP facilitates disposition of endogenous and exogenous harmful xenobiotics to protect 
cells/tissues from xenobiotic-induced toxicity. Despite the enormous impact of BCRP in the 
physiological and pathophysiological regulation of the transport of a wide variety of substrates, 
little is known about the factors that regulate posttranslational expression of BCRP. Here, we 
identified Derlin-1, a member of a family of proteins that bears homology to yeast Der1p, as a 
posttranslational regulator of BCRP expression. Overexpression of Derlin-1 suppressed ER to 
Golgi transport of wild-type (WT) BCRP that is known to be efficiently trafficked to the plasma 
membrane. On the other hand, protein expression of N596Q variant of BCRP, N-linked 
glycosylation- deficient mutant that preferentially undergoes ubiquitin-mediated ER-associated 
degradation (ERAD), was strongly suppressed by the overexpression of Derlin-1, whereas 
knockdown of Derlin-1 stabilized N596Q protein, suggesting a negative regulatory role of 
Derlin-1 for N596Q protein expression. Notably, knockdown of Derlin-1 also stabilized the 
expression of tunicamycin-induced deglycosylated WT BCRP protein, implying the importance of 
glycosylation state for the recognition of BCRP by Derlin- 1. Thus, our data demonstrate that 
Derlin-1 is a negative regulator for both glycosylated and non-glycosylated BCRP expression and 
provide a novel posttranslational regulatory mechanism of BCRP by Derlin-1.
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1. Introduction
Human ATP-binding cassette (ABC) transporters are membrane transporters that use energy 
from ATP hydrolysis to transport a wide variety of substrates across the cellular membrane 
[1]. To date, 48 members of the human ABC transporters genes have been identified and 
cloned. Of these, breast cancer resistance protein (BCRP)/MXR/ABCG2 is a well-
recognized ABC half-transporter that is highly expressed at the apical membrane of many 
normal tissues [2,3]. BCRP mediates efflux transport of a large number of endogenous and 
exogenous harmful xenobiotics and facilitates disposition of these substrates, which results 
in protecting cells/tissues from xenobiotic-induced toxicity. Recent works on the use of 
Abcg2−/− mice have further revealed that BCRP is involved in extrusion of porphyrins, 
vitamin B2 (riboflavin) and other vitamins (biotin, vitamin K) [4]. Moreover, BCRP was 
also identified as a urate secretory transporter with a common functional genetic 
polymorphism causing gout [5].
Despite the enormous impact of BCRP in the physiological regulation of the transport of a 
wide variety of substrates, overexpression of BCRP in cancer cells reduces intracellular 
concentration of anticancer drugs, which dampens cytotoxic effects of these drugs [6]. 
Consistently, it has been reported that a correlation exists between BCRP expression and 
patient outcome in some hematologic and solid tumors [7], suggesting that identification of 
the regulatory mechanisms responsible for the expression and function of BCRP may help 
us to circumvent BCRP-mediated drug resistance and improve anti-cancer therapies.
The expression level of BCRP protein is regulated by both transcriptional and 
posttranslational mechanisms. Recent reports on the posttranslational regulation of BCRP 
suggested that monitoring the quality of BCRP protein in the endoplasmic reticulum (ER) is 
critical for the regulation of BCRP expression [8]. For example, not wild-type (WT) but 
N596Q variant of human BCRP, in which N-linked glycosylation was predicted not to occur 
at all, was susceptible to ER-associated degradation (ERAD) [9]. Moreover, the certain 
single nucleotide polymorphism (SNP) variants of BCRP (Q141K, F208S and S441N), 
which protein expression was markedly low despite the functional expression of mRNA, 
were also degraded by ERAD [10,11]. Although ER seems to be strongly associated with 
the expression level of BCRP, the molecules that are critical for the control of these 
posttranslational regulations are yet to be fully understood.
In the present study, we first screened ER-localized E3 ubiquitin ligases and their co-factor 
that functions in the regulation of WT and N596Q variant of BCRP expression and 
identified Derlin-1, a member of a family of proteins that bears homology to yeast Der1p 
[12], as a negative regulator for both glycosylated and non-glycosylated BCRP expression. 
In addition, we demonstrated that the difference was observed between WT and N596Q 
variant of BCRP with respect to the mechanism underlying negative regulation of BCRP by 
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Derlin-1. Our data provide a novel posttranslational regulatory mechanism of BCRP by 
Derlin-1.
2. Materials and methods
2.1. Materials
Reagents, antibodies, DNA constructs and RNAi constructs used in this study are described 
in the Supplemental data.
2.2. Cell culture and transfection
General method for cell culture, cycloheximide (CHX) chase and brefeldin A (BFA) wash 
out experiments in this study are described in the Supplemental data. Transient transfections 
of plasmids were performed using either Trans-IT LT1 (Mirus, Madison, WI) or Hilymax 
(Dojin Co. Ltd, Tokyo, Japan) by following the manufacturer’s recommendations as 
described earlier [13,14]. For the transfection of si-RNAs, Trans-IT TKO (Mirus) was used 
as previously described [15]. Fifty nanomolar of si-Derlin-1 and Stealth™ RNAi negative 
Universal Control (control siRNA) were transfected into 90% confluent cells to knockdown 
Derlin-1. The cells were harvested 48 h after transfection.
2.3. SDS–PAGE, Western blotting and immunoprecipitation
Confluent (90–100%) cells grown on 60 mm dishes were used for collect the cell lysates and 
are subjected to SDS–PAGE, followed by Western blotting as described earlier [8]. For N-
glycanases digestion, cell lysates were denatured at 37 °C for 30 min and digested with 
Endo H (500 U) or PNGase F (500 U) at 37 °C for 90 min. Method on immunoprecipitation 
with anti-GFP antibody is described in the Supplemental data.
2.4. Immunocytochemical analysis
Immunocytochemical analysis was performed as described previously [16]. BCRP-GFP-
transfected HeLa cells were stained with anti-KDEL antibody and Alexa Flour 546 
conjugated secondary antibody (Molecular Probes, Eugene, OR).
2.5. Statistical analysis
For quantitative analysis, result represents the mean ± SEM performed in triplicate and the 
data were analyzed by Student’s t-test (JMP software, SAS Institute).
3. Results
3.1. Screening of ER-localized factors that function in the regulation of WT and N596Q 
variant of BCRP expression
Although the posttranslational modification and ERAD of BCRP are becoming of great 
interest [8], there is only limited information on the specific factors that are critical for the 
regulation of BCRP expression. In the present study, we focused on WT and N596Q variant 
of BCRP. WT BCRP was used as a representative of BCRP proteins that is efficiently 
glycosylated and folded in the ER and transported to the plasma membrane (PM) [8]. 
Consistently, our analysis of the expression pattern of WT BCRP in HEK293 cells showed 
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dominant expression of Endo H-resistant form of BCRP, which can be considered as 
complex-glycosylated (C-G) form that localizes in the golgi or PM (Fig. 1A, upper pannel). 
There were also a few expression of simply-glycosylated (S-G) form of BCRP in WT-
BCRP- transfected HEK293 cells as determined by Endo H and PNG-ase F digestions (Fig. 
1A, upper pannel). Whereas N596Q BCRP, in which Asn596 is substituted by Gln596, 
preferentially undergoes ERAD because of the lack of N-linked glycosylation although its 
PM targeting and transporter activity are less affected if it is trafficked from the ER to PM 
[9]. We also checked the expression pattern of N596Q BCRP in HEK293 cells and 
confirmed the expression of non-glycosylated (Non-G) form of BCRP (Fig. 1A, lower 
pannel). Since ER is considered as an important organelle to determine the fate of these 
BCRP proteins, we first screened ER-localized factors that functions in the regulation of 
BCRP expression. Screening was performed by the change of BCRP expression level and 
pattern after the overexpression of ER-localized E3 ubiquitin ligases (WT gp78, WT Rma1, 
WT HRD1 and WT CHIP) and co-factor Derlin-1 that are previously shown to be involved 
in the degradation of several ABC transporters [17–19]. We also tried the overexpression of 
E3 activity-deficient dominant-negative mutant form of these E3 ligases (gp78 R2M, Rma1 
C42S, HRD1 C329S and CHIP H260Q) in this study. Notably, none of WT and dominant-
negative mutant form of E3 ligases did not robustly affect the expression level and pattern of 
both WT and N596Q BCRP (Fig. 1B–E), while overexpression of Derlin-1 strongly reduced 
81 kDa band (possibly C-G form) and increased 72 kDa band (possibly S-G form) of WT 
BCRP (Fig. 2F). More interestingly, Derlin-1 overexpression strongly inhibited the 
expression level of N596Q BCRP (Fig. 2G). Thus, these data suggest that Derlin-1, but not 
other known E3 ligases tested, may be the critical molecule to control the expression of both 
WT and N596Q BCRP proteins.
3.2. Exogenous Derlin-1 negatively regulates WT BCRP expression via inhibition of ER-to-
Golgi transport of WT BCRP
Having demonstrated that Derlin-1 overexpression dominantly increased the 72 kDa band of 
WT BCRP protein, we next evaluated the origin of this dominant band. The 72 kDa band 
was sensitive to Endo H digestion, confirming that Derlin-1 strongly increased S-G form of 
BCRP expression (Fig. 2A). Since decreased C-G form of BCRP was also accompanied 
with an increased expression of S-G form during Derlin-1 overexpression, we sought to 
determine whether ER-to-Golgi transport of WT BCRP is affected in Derlin-1-transfected 
HEK293 cells. As shown in Fig. 2B, treatment of brefeldin A (BFA), a ER-to-Golgi 
transport inhibitor [20], increased accumulation of ER form of WT BCRP (S-G) 
(pcDNA3.1, 0 min) and this band was gradually converted to C-G form of BCRP after the 
removal of BFA from culture media (BFA wash out). On the other hand, ER-to-Golgi 
transport of WT BCRP was significantly inhibited in the presence of exogenous Derlin-1 
(Fig. 2B and C). Furthermore, WT BCRP-GFP expression was strongly limited in the ER in 
the presence but not the absence of exogenous Derlin-1 (Fig. 2D) and C-G form of WT 
BCRP-GFP was also converted to S-G form during Derlin-1 overexpression (Fig. 2E). Since 
interaction was observed between WT BCRP-GFP and Derlin-1 in the condition of Derlin-1 
overexpression (Fig. 2F), these data suggest that Derlin-1 suppresses the maturation of WT 
BCRP protein possibly through their direct interaction.
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To exclude the possible role of Derlin-1 in regulating degradation of WT BCRP, protein 
stability in Derlin-1-transfected cells was evaluated by the cycloheximide (CHX) chase 
experiment. As shown in Fig. 2G and H, PNGase F-treated (+) WT BCRP expression, which 
represents total amount of WT BCRP protein, was minimally affected in Derlin-1-
transfected cells during the CHX chase period. Moreover, knockdown of Derlin-1 by siRNA 
did not have any impact on the expression of WT BCRP (Fig. 2I), suggesting that 
endogenous Derlin-1 may not function as a regulator of WT BCRP expression. Taken 
together, our data imply that exogenous but not endogenous level of Derlin-1 could 
negatively regulate the WT BCRP expression via the inhibition of ER-to Golgi transport of 
WT BCRP.
3.3. Derlin-1 facilitates ERAD of N596Q BCRP protein via reduction of its protein stability
Since Derlin-1 overexpression suppressed expression of N596Q BCRP protein (Fig. 1G), we 
hypothesized that Derlin-1 could facilitate ERAD of N596Q BCRP protein. Treatment with 
MG-132, a proteasome inhibitor [21], caused increased expression of N596Q BCRP protein, 
which is consistent with the previous study that showed that N596Q BCRP is relatively 
susceptible to ERAD (Fig. 3A) [9]. Interestingly, knockdown of Derlin-1 significantly 
increased the expression of N596Q BCRP protein to a similar extent as MG-132 treatment 
(Fig. 3B and C), implying the possible involvement of Derlin-1 in the regulation of N596Q 
BCRP degradation. Accordingly, significant reduction of N596Q BCRP expression was 
observed in the presence of Derlin-1 after 6 h CHX chase period (Fig. 3D and E), suggesting 
that both endogenous and exogenous Derlin-1 could reduce stability of N596Q protein and 
may contribute to ERAD of N596Q BCRP.
3.4. Derlin-1 could also facilitate ERAD of non-glycosylated form of WT BCRP
Recent report demonstrated that N-linked glycan is important for stabilizing WT BCRP and 
that disruption of this linkage by tunicamycin, a N-linked glycosylation inhibitor, results in 
protein destabilization and enhanced ERAD [9]. Based on our finding that Derlin-1 
facilitates ERAD of non-glycosylated form of BCRP protein, N596Q BCRP, it is quite 
reasonable to think that Derlin-1 is also involved in tunicamycin-induced degradation of WT 
BCRP. Consistently, tunicamycin converted the expression pattern of WT BCRP from C-G 
form to Non-G form in WT BCRP-transiently transfected- HEK293 cells (Fig. 4A) and 
therefore significantly reduced the amount of WT BCRP expression (Fig. 4B). Further, 
pretreatment with MG132 inhibited the effect of tunicamycin-dependent change of band 
patten and expression of WT BCRP (Fig. 4C), confirming the existence of tunicamycin-
induced degradation of WT BCRP in our system. Interestingly, significant inhibition of 
tunicamycin-induced degradation of WT BCRP was also observed by knockdown of 
Derlin-1 (Fig. 4D and E), suggesting that Derlin-1 could also facilitate ERAD of non-
glycosylated form of WT BCRP.
4. Discussion
ER is a crucial organelle that controls the proper balance between the posttranslational 
events that promote productive folding and ERAD of newly synthesized secretory and 
integral membrane proteins including disease-associated ABC transporters [8,22]. Among 
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these transporters, cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) is 
one of the best characterized ABC transporters in terms of the posttranslational quality 
control in the ER [22–24]. Accumulating evidences have demonstrated that several E3 
ubiquitin ligases, such as CHIP, gp78 and Rma1, and its co-factor Derlin1 are important 
factors that control cellular homeostasis by facilitating the degradation of WT or mutant 
CFTR [17,18,25]. These results lead us to speculate on possible involvement of these factors 
for the posttranslational regulation of other ABC transporters including BCRP/ABCG2. 
Here, we identified Derlin- 1 as a vital factor that affects both glycosylated and non-
glycosylated BCRP expression by different mechanisms (Fig. 4F). In the regulation of 
glycosylated WT BCRP, exogenously expressed Derlin- 1 seems to induce ER retention of 
BCRP protein by inhibiting ER to Golgi transport. On the other hand, Derlin-1 is likely to be 
an ERAD mediator of N-linked glycosylation-deficient mutant N596Q BCRP and 
tunicamycin-induced non-glycosylated WT-BCRP proteins.
It is still unclear how Derlin-1 regulates the expression of these BCRP proteins. Since 
physical interaction was observed between exogenously expressed Derlin-1 and WT BCRP 
protein (Fig. 2F), Derlin-1 may regulate WT BCRP trafficking through their direct 
interaction. However, no interaction was observed between endogenously expressed 
Derlin-1 and WT BCRP protein (Fig. 2F) and siDerlin-1 did not affect the WT BCRP 
protein status (Fig. 2I), implying that Derlin-1 functions as a regulator of WT BCRP only if 
it is overexpressed. Since there are only limited number of studies on the regulation of 
Derlin-1 expression, a causal relationship between Derlin-1-BCRP interaction and WT-
BCRP expression levels needs to be further investigated in many types of cells to explore 
the impact of their interaction. Meanwhile, our study also did not elucidate the mechanism 
responsible for the Derlin-1-induced non-glycosylated BCRP degradation. Increasing 
evidences suggest that Derlin-1 has a chaperone-like activity that allows it to function as a 
substrate selector for the specific E3 ligase complex such as Rma1 [18,25,26]. Notably, 
overexpression of WT form of Rma1 and HRD1 but not dominant negative form of Rma1 
(C42S) and HRD1 (C329S) seemed to slightly decrease N596Q BCRP expression (Fig. 1C 
and D), implicating that Derlin-1 may work with Rma1 and/or HRD1 during non-
glycosylated BCRP degradation. Further studies are needed to identify the co-factors with 
Derlin-1.
One key issue that has yet to be discussed is how Derlin-1 recognizes non-glycosylated 
BCRP as its substrate for ERAD. Whether it is the absence of glycosylation or of protein 
instability in the ER requires further study. In order to explore these possibility, we need to 
assess the effect of Derlin-1 knockdown on the expression of BCRP variant proteins which 
are known to undergo ERAD in a glycosylation state-independent manner. These include 
naturally occurring SNPs variants of BCRP such as Q141K, F208S and S441N [10,11]. 
Further, we could also assess the impact of Derlin- 1 on the expression of other BCRP 
variants such as R383A, G553L and G553E variants, which are also shown to be impaired 
N-linked glycosylation like N596Q BCRP [27,28]. Whether siDerlin- 1 stabilizes the above 
BCRP variant proteins is currently under investigation.
Overall, our data demonstrate that Derlin-1 interacts physically with WT BCRP and reduces 
its maturation, and Derlin-1 initiates the efficient ERAD of non-glycosylated WT and 
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N596Q BCRP, indicating that Derlin-1 is the negative regulator for the expression of both 
glycosylated and non-glycosylated WT BCRP proteins. Although current study does not rule 
out the involvement of Derlin- 1 in the regulation of BCRP function such as transport 
activity, our results provide a novel posttranslational regulatory mechanism of BCRP by 
Derlin-1.
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Derlin-1 is the critical molecule to control the expression of both WT and N596Q BCRP 
proteins. (A) HEK293 cells were transfected with WT or N596Q variant BCRP. Cell lysates 
were denatured and digested with Endo H or PNGase F. C-G, S-G and Non-G indicate 
complex-glycosylated, simply-glycosylated and non-glycosylated form of BCRP proteins, 
respectively. (B–E) WT or N596Q BCRP-transfected HEK293 cells were co-transfected 
with empty vectors or expression vectors that encode either WT or dominant-negative 
mutants of myc-tagged gp78 (B), Flag-tagged Rma1 (C), myc-tagged HRD1 (D) and myc-
tagged CHIP (E). (F–G) Empty vector pcDNA3.1 or HA-tagged Derlin-1 was co-transfected 
with WT (F) or N596Q (G) BCRP in HEK293 cells. Exo-Derlin-1 and Endo Derlin-1 
indicate exogenously and endogenously expressed Derlin-1, respectively. In all the 
experiments, whole cell lysates were subjected to Western blotting with the indicated 
antibodies. Actin was used as internal control.
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Derlin-1 negatively regulates WT BCRP expression via inhibition of ER-to Golgi transport 
of WT BCRP. (A) WT BCRP-transfected HEK293 cells were co-transfected with Derlin-1. 
Cell lysates were denatured and digested with Endo H or PNGase F, followed by Western 
blotting with anti-BCRP antibody. (B and C) WT BCRP-transfected HEK293 cells were co-
transfected with empty vector pcDNA3.1 or HA-tagged Derlin-1. After transfection, cells 
were treated with 5 μg/mL of BFA for 6 h and then media was refreshed. Cells were 
harvested at 0, 90 and 180 min after BFA wash out and subjected to Western blotting (B). 
Band intensities were measured by using Image Gauge software and relative maturation 
ratio was expressed as (intensity of C-G form)/(intensity of S-G form + intensity of C-G 
form) (C). *P < 0.05 vs. pcDNA3.1-transfected cells. (D and E) Empty vector pcDNA3.1 or 
HA-tagged Derlin-1 was co-transfected into HeLa cells with GFP-tagged WT BCRP. Cells 
were fixed and localization of WT BCRP-GFP was determined by confocal laser scanning 
microscopy. To visualize ER, immunofluorescence analysis was performed with anti-KDEL 
antibody. (E and F) WT BCRP-GFP-transfected HEK293 cells were transfected with empty 
vector pcDNA3.1 or HA-tagged Derlin-1. Cells were lysed in digitonin buffer after 
transfection and lysates were subjected to Western blotting (E) and immunoprecipitation 
analysis (F). WT BCRP-GFP protein was immunoprecipitated by using anti-GFP antibody 
or non-immunized IgG (con-IgG) and immunoprecipitants were analyzed by Western 
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blotting. (G and H) WT BCRP-transfected HEK293 cells were co-transfected with empty 
vector pcDNA3.1 or HA-tagged Derlin-1. Twenty-four hours after transfection, cells were 
treated with 50 μMof CHX and harvested at 0, 12 and 24 h after CHX treatment. Whole cell 
lysates were subjected to Western blotting (G). PNGase F-digested WT BCRP intensity was 
measured to express total BCRP amounts (H). Result represents the mean + or −SEM 
performed. *P < 0.05 vs. pcDNA3.1- transfected cells. (I) WT BCRP-transfected HEK293 
cells were co-transfected with 50 nM of control (−) or specific siRNA for Derlin-1 (+), 
followed by Western blotting.
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Derlin-1 facilitates ERAD of N596Q BCRP protein via reduction of its protein stability. (A) 
N596Q BCRP-transfected HEK293 cells were treated with 5 μM of MG132 for 24 h and 
lystaes were subjected to Westen blotting. (B and C) N596Q BCRP-transfected HEK293 
cells were co-transfected with 50 nM of control (−) or specific siRNA for Derlin-1 (+), 
followed by Western blotting (B). Band intensities were measured (C). *P < 0.05 vs. control 
siRNA-transfected cells. (D, E) N596Q BCRP-transfected HEK293 cells were co-
transfected with empty vector pcDNA3.1 or HA-tagged Derlin-1. After transfection, cells 
were treated with 200 μM of CHX and harvested at 0, 3 and 6 h after CHX treatment. Whole 
cell lysates were subjected to Western blotting (D). Non-G N596Q BCRP intensity was 
measured to express total BCRP amounts (E). *P < 0.05 vs. pcDNA3.1- transfected cells.
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Derlin-1 also facilitates ERAD of non-glycosylated form of WT BCRP. (A) WT BCRP-
transfected HEK293 cells were treated with various concentration of tunicamycin for 16 h, 
followed by Western blotting. (B) Band intensities of tunicamaysin-treated samples (1 
g/mL) were measured. Band intensities of (C-G WT BCRP)+(Non-G WT BCRP) were 
calculated to express total BCRP amounts.*P < 0.05 vs. non-treated cells. (C) WT BCRP-
transfected HEK293 cells were treated with 1 g/mL of tunicamycin in the presence or 
absence of 5 M of MG-132 for 16 h, followed by Western blotting. (D and E) WT BCRP-
transfected HEK293 cells were co-transfected with 50 nM of control (−) or specific siRNA 
for Derlin-1 (+). After transfection, cells were treated with 2 g/mL of tunicamycin for 16 h, 
followed by Western blotting. Band intensities of (C-G WT BCRP)+(Non-G WT BCRP) 
were calculated to express total BCRP amounts. *P < 0.05 vs. tunicamycin-treated, control 
siRNA-transfected cells. (F) Schematic flow of Derlin1-dependent posttranslational 
regulation of glycosylated and non-glycosylated WT or N596Q BCRP. Derlin-1 physically 
interacts with WT BCRP and reduces its maturation, and Derlin-1 initiates the efficient 
ERAD of non-glycosylated WT or N596Q BCRP. Tunicamycin increases Non-G BCRP. 
MG-132 inhibits ERAD of Non-G WT-BCRP and N596Q BCRP.
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